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2NA signature for assessment of future tuberculosis risk 
ak DE, Penn-Nicholson A, Scriba TJ, et al. A blood RNA
ignature for tuberculosis disease risk: a prospective cohort
tudy. Lancet. 2016 Jun 4;387(10035):2312–22. doi: 10.1016/S0140-
736(15)01316–1. 
Treatment of latent tuberculosis infection (LTBI) is neither feasi-
le nor recommended in countries where tuberculosis is endemic.
urrent commercially available blood testing cannot distinguish la-
ent TB from active TB, nor does it determine who is at risk for
eveloping reactivation of latent tuberculosis. Identifying patients
t risk for progressing from latent to active disease however, may
e helpful in targeting prophylactic treatment and thus assisting in
he ﬁght against the global TB epidemic. Berry and colleagues pre-
iously described a gene signature that could differentiate active
B infection from LTBI. [1] Zak and colleagues aimed to identify
 gene signature that could identify healthy individuals at risk for
eveloping tuberculosis for up to 2 years. 
In this prospective cohort study, the investigators enrolled 6363
IV-negative individuals aged 12–18 years from the South African
dolescent cohort study (ACS) and assessed them every 6 months
or 2 years. They identiﬁed 46 people who progressed to active
B infection and 107 matched controls. Participants were randomly
ssigned to either a training set or a test set. The training set was
sed to develop a tuberculosis risk signature by mining a whole
lood sequencing dataset, which was cross-validated. The signature
as composed of 16 genes, which became more expressed as the
uberculosis diagnosis approached. The predictive potential of tu-
erculosis progression in the training group found a sensitivity of
1.2% at 6 months, 62.9% at 6–12 months at a speciﬁcity of 80.6%,
nd 47.7% at 12–18 months before TB diagnosis. The tuberculosis
isk signature was then applied to a qRT-PCR platform and used to∗ Fax: 507 538 0 0 01. 
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(2016), http://dx.doi.org/10.1016/j.jctube.2016.11.001 redict TB risk in the test set. The sensitivity was 66.1% and speci-
city was 80.6% in the 12 months preceding TB diagnosis. 
The investigators went on to apply the tuberculosis risk sig-
ature to predict TB risk in other HIV-negative cohorts including
466 individuals in South Africa and Gambia, aged 10–60 years
ith a sputum spear positive household contact. They were fol-
owed for 2 years. Sensitivity of the risk signature was 53.7% and
peciﬁcity was 82.8% in the year preceding TB infection. 
Given the increase in gene expression as active TB diagnosis ap-
roached, the gene signature was also used to determine individ-
als with active TB infection from those LTBI and uninfected con-
rols in other studies of HIV-uninfected South African adults, and
ound to have an 87% sensitivity and 97% speciﬁcity. Furthermore,
ene expression was found to decrease over time when applied to
hose being treated for active TB over 6 months. 
These results show promise in the area of blood-based gene sig-
atures to identify individuals at risk for developing active TB in-
ection. Further studies are necessary to determine whether this
latform would be useful in other populations, particularly in
hose with HIV or other co-infections, where a tremendous burden
f disease exists. 
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pTreatment Mycobacterium avium complex (MAC) becomes ex-
tremely challenging in the face of macrolide-resistance. The 2007
ATS and IDSA statement compared management of these infections
to that of multidrug resistant tuberculosis (MDR-TB). [1] Random-
ized controlled trials studying the eﬃcacy of second line agents
for pulmonary MAC are diﬃcult to conduct given the heterogene-
ity of patients. Morimoto and colleagues aimed to describe the fac-
tors associated with development of macrolide resistance, as well
as the outcomes and prognosis of individuals with macrolide resis-
tant pulmonary MAC. 
In this retrospective observational study, 102 cases of
macrolide—resistant MAC lung disease were reviewed between
2005 and 2013. Cases were identiﬁed in 3 tertiary hospitals in
Toyo and one hospital from Aichi prefecture. MDR-TB cases were
also reviewed from Fukujuji Hospital for comparison of survival
rates. Of the 102 cases, 90 met criteria. A majority of patients were
women with lower BMIs and a median age of 68 years at the
conﬁrmation of macrolide resistance. The disease type was evenly
distributed among nodular, ﬁbrocavitary, and complex pulmonary
disease. The rate of inappropriate ﬁrst line treatment was high
(58.9%) including clarithromycin monotherapy, clarithromycin plus
a ﬂuoroquinolone, and treatments without ethambutol. Adverse
effects of treatment were common, including ethambutol (34.4%),
rifampin (17.8%), aminoglycosides (7.8%), ﬂuoroquinolones (5.6%)
and clarithromycin (4.4%). Surgeries were performed on 12.2%
of patients. The majority (63.3%) of patients showed worsened
radiographic ﬁndings, 22.2% were unchanged, and only 16.7% were
improved. 
Multiple logistic regression analysis was done to stratify factors
that were associated with better prognosis including demograph-
ics, disease type, discontinuation of clarithromycin, and addition of
another treatment: ﬂuoroquinolone, rifabutin, an aminoglycoside,
and surgery. Surgery was correlated with improved outcomes (ad-
justed OR = 5.81) but this was not statistically signiﬁcant. Only the
combination of an aminoglycoside plus surgery had a signiﬁcant
association with a better prognosis (OR 29.1, p = 0.01). The ﬁve year
survival was 71%, and similar to the 75% survival rate of MDR-TB. 
Although this study has limitations of being a retrospective
observational study, it highlights the contribution of inappropri-
ate treatment prior the detection of macrolide-resistant MAC pul-
monary disease. There are several reasons for this including treat-
ment of other comorbidities, such as bronchiectasis, for which
macrolides are often used for antiinﬂammatory purposes. Fur-
thermore, ethambutol drug toxicity often prevents patients from
receiving ﬁrst line therapy. The improved outcomes in patients
treated with surgery, particularly in combination with aminoglyco-
sides, conﬁrms what other investigators have shown. [2,3] Larger
controlled trails are needed to better identify more optimal treat-
ment regimens, and novel drugs are desperately needed in the
hopes of offering better outcomes for these diﬃcult to treat cases. 
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With increasing immunosuppressive therapies for treatment of
alignancies and inﬂammatory disorders, rates of nontuberculous
ycobacterial infections have been on the rise. Although positive
cid fast staining on specimens can identify the presence of my-
obacterial organisms early, it is not sensitive, nor can it distin-
uish between species. Current identiﬁcation methods rely heavily
pon culture growth, which can take days to weeks, delaying early
reatment initiation in most cases. PCR probes have been devel-
ped to distinguish tuberculosis from other nontuberculous my-
obacteria (NTMs); however a rapid screen that can detect pres-
nce of several NTM organisms would be of great beneﬁt. Scoleri
nd colleagues describe a TaqMan quantitative PCR assay for de-
ection of a large range of NTM species from respiratory samples. 
The investigators developed an assay using 116 available heat-
hock protein 65 (hsp65) NTM gene sequences, including the 56
TM species known to cause respiratory infection. They went on to
est the assay’s ability to identify NTM species from several known
solates, including 15 NTM strains and negative controls consisting
f 15 other NTMs, 9 TB strains, other respiratory pathogens, and
uman DNA. Sensitivity was assessed by dilutions methods using
. abscessus DNA. The assay was validated using 42 clinical res-
iratory samples, including sputum and BAL samples, from indi-
iduals with suspected NTM infection. Of these specimens, 8 were
ound to be culture-positive for NTM species and these were con-
ormed conﬁrmed by qPCR and DNA sequencing. Species identiﬁed
ncluded M. avium, M. abscessus, M. intracellulare, M. massiliense.
hree samples were culture negative and qPCR positive. These in-
luded a case with high levels of H inﬂuenza growth, one who had
eceived prior therapy for another NTM species, and one sample
hat was “insuﬃcient for adequate assessment.”
This study shows great promise in the development of a rapid
ssay for detection of clinically relevant NTM species. A limita-
ion to this study includes small sample size. The investigators ac-
nowledge that PCR assays detect viable and nonviable bacterial
ells; therefore a positive result may not necessarily be indicative
f infection. Further studies are needed to validate this assay. Ar-
as for future research include application to other non-respiratory
amples and assessment of other NTM species implicated in non-
ulmonary disease. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases 
